Summit Therapeutics Quarterly Balance Sheet
NASDAQ: SMMTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Summit Therapeutics financial position
As of Jun 30, 2026, Summit Therapeutics reported total assets of $752.2 million, up 132.1% from a year earlier against total liabilities of $122.2 million. Shareholders' equity stood at $630.0 million, or 83.8% of assets. The company held $419.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 6.96, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Summit Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 419.37M | 106.52M | 225.27M | 238.55M | 297.87M | 211.53M | 104.86M | 93.78M | 28.43M | 61.29M | 71.42M | 23.79M |
| Short-Term Investments | 271.31M | 492.22M | 488.18M | 0 | 0 | 149.79M | 307.49M | 393.12M | 297.04M | 95.39M | 114.82M | 175.15M |
| Receivables | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Total Current Assets | 720.58M | 616.60M | 720.30M | 246.47M | 309.24M | 370.75M | 423.75M | 490.29M | 328.79M | 163.26M | 189.71M | 204.95M |
| Property, Plant & Equipment | 1.78M | 1.66M | 1.06M | 810.00K | 690.00K | 652.00K | 254.00K | 265.00K | 223.00K | 181.00K | 204.00K | 229.00K |
| Goodwill | 1.97M | 1.97M | 2.00M | 2.00M | 2.04M | 1.92M | 1.86M | 1.99M | 1.88M | 1.88M | 1.89M | 1.81M |
| Intangible Assets | — | — | — | — | — | — | 0 | — | — | — | 0 | 0 |
| Total Assets | 752.18M | 647.86M | 751.18M | 261.73M | 324.04M | 383.82M | 435.56M | 502.85M | 341.86M | 176.78M | 202.95M | 218.48M |
| Accounts Payable | 22.90M | 27.55M | 20.29M | 22.25M | 22.98M | 4.99M | 4.64M | 3.25M | 3.34M | 6.37M | 2.67M | 3.31M |
| Total Current Liabilities | 103.57M | 83.27M | 72.99M | 64.93M | 60.33M | 34.88M | 41.73M | 59.01M | 140.17M | 23.44M | 20.41M | 113.74M |
| Long-Term Debt | — | — | — | — | — | — | 0 | 0 | 0 | 100.00M | 100.00M | 0 |
| Total Liabilities | 122.20M | 101.92M | 92.32M | 69.47M | 64.60M | 39.49M | 46.81M | 64.93M | 146.78M | 132.57M | 125.26M | 119.10M |
| Shareholders' Equity | 629.98M | 545.93M | 658.86M | 192.26M | 259.44M | 344.33M | 388.75M | 437.92M | 195.07M | 44.21M | 77.69M | 99.38M |
| Retained Earnings | -2.70B | -2.48B | -2.29B | -2.07B | -1.84B | -1.28B | -1.21B | -1.15B | -1.10B | -1.04B | -993.26M | -956.69M |
| Total Debt | — | — | — | — | — | — | 0 | 0 | 0 | 100.00M | 100.00M | 0 |
| Net Cash (Debt) | 690.68M | 598.73M | 713.45M | 238.55M | 297.87M | 361.31M | 412.35M | 486.90M | 325.47M | 56.68M | 86.24M | 198.94M |
| Shares Outstanding | 793.12M | 776.02M | 775.37M | 744.44M | 742.81M | 741.61M | 737.63M | 737.09M | 724.32M | 701.97M | 701.66M | 697.85M |
This table shows 12 quarterly periods of Summit Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow SMMT's reporting calendar. What is a balance sheet?